Martín Jesús García González

Martín Jesús García González

Auto-generated profile, based on publicly available information

Martín Jesús García González

Acute Cardiac Care Unit, Complejo Hospitalario Universitario de Canarias , Servicio Canario de la Salud, carretera La Cuesta - Taco, Ofra s/n, San Cristóbal de La Laguna, Santa Cruz de Tenerife, 38320

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 April 2014 in International Journal of Cardiology
Verified
Journal Article
Open access
PDF file
MNM.S. Nieminen
M.S. Nieminen
JAJ. Altenberger
J. Altenberger
TBT. Ben-Gal
T. Ben-Gal
ABA. Böhmer
A. Böhmer
JCJosep Comín-Colet
Josep Comín-Colet
GWG. Wikström
G. Wikström
The intravenous inodilator levosimendan was developed for the treatment of patients with acutely decompensated heart failure. In the last decade scientific and clinical interest has arisen for its repetitive or intermittent use in patients with advanced chronic, but not necessarily acutely decompensated, heart failure. Recent studies have suggested long-lasting favourable effects of levosimendan when administered repetitively, in terms of haemodynamic parameters, neurohormonal and inflammatory markers, and clinical outcomes. The existing data, however, requires further exploration to allow for definitive conclusions on the safety and clinical efficacy of repetitive use of levosimendan. A panel of 30 experts from 15 countries convened to review and discuss the existing data, and agreed on the patient groups that can be considered to potentially benefit from intermittent treatment with levosimendan. The panel gave recommendations regarding patient dosing and monitoring, derived from the available evidence and from clinical experience. The current data suggest that in selected patients and support out-of-hospital care, intermittent/repetitive levosimendan can be used in advanced heart failure to maintain patient stability. Further studies are needed to focus on morbidity and mortality outcomes, dosing intervals, and patient monitoring. Recommendations for the design of further clinical studies are made.

24 May 2020 in Journal of Cardiothoracic Surgery
Verified
Journal Article
Open access
PDF file
JJJuan José Jiménez-Rivera
Juan José Jiménez-Rivera
AÁAndrea Álvarez-Castillo
Andrea Álvarez-Castillo
JFJorge Ferrer-Rodríguez
Jorge Ferrer-Rodríguez
JIJosé Luis Iribarren-Sarrías
José Luis Iribarren-Sarrías
MGMartín Jesús García-González
Martín Jesús García-González
RMRafael Martínez-Sanz
Rafael Martínez-Sanz
Background: Patients with moderate-severe systolic dysfunction undergoing coronary artery bypass graft have a higher incidence of postoperative low cardiac output. Preconditioning with levosimendan may be a useful strategy to prevent this complication. In this context, design cost-effective strategies like preconditioning with levosimendan may become necessary. Methods: In a sequential assignment of patients with Left Ventricle Ejection Fraction less than 40%, two strategies were compared in terms of cost-effectiveness: standard care (n = 41) versus preconditioning with Levosimendan (n = 13). The adverse effects studied included: postoperative new-onset atrial fibrillation, low cardiac output, renal failure and prolonged mechanical ventilation. The costs were evaluated using deterministic and probabilistic sensitivity analysis, and Monte Carlo simulations were performed. Results: Preconditioning with levosimendan in moderate to severe systolic dysfunction (Left Ventricle Ejection Fraction < 40%), was associated with a lower incidence of postoperative low cardiac output in elective coronary artery bypass graft surgery 2(15.4%) vs 25(61%) (P < 0.01) and lesser intensive care unit length of stay 2(1–4) vs 4(3–6) days (P = 0.03). Average cost on levosimendan group was 14,792€ while the average cost per patient without levosimendan was 17,007€. Patients with no complications represented 53.8% of the total in the levosimendan arm, as compared to 31.7% in the non-levosimendan arm. In all Montecarlo simulations for sensitivity analysis, use of levosimendan was less expensive and more effective. Conclusions: Preconditioning with levosimendan, is a cost-effective strategy preventing postoperative low cardiac output in patients with moderate-severe left ventricular systolic dysfunction undergoing elective coronary artery bypass graft surgery.

1 January 2004 in American Journal of Cardiovascular Drugs
Verified
Journal Article
Closed access
PDF file
Alberto Dominguez-RodriguezAlberto Dominguez-Rodriguez
Alberto Dominguez-Rodriguez
MGM. Garcia-Gonzalez
M. Garcia-Gonzalez
PAP. Abreu-Gonzalez
P. Abreu-Gonzalez

30 October 2026 in European Journal of Cardiovascular Nursing
Verified
Journal Article
Closed access
ELEmilio Siverio Lorenzo
Emilio Siverio Lorenzo
MGMartín Jesús García González
Martín Jesús García González
AJAlejandro Jiménez-Sosa
Alejandro Jiménez-Sosa

1 May 2023 in European Heart Journal: Acute Cardiovascular Care
Verified
Journal Article
Open access
PDF file
PPP Jorge Perez
P Jorge Perez
MGM J Garcia-Gonzalez
M J Garcia-Gonzalez
MMM M Martin-Cabeza
M M Martin-Cabeza
SLSergio Luis-Lima
Sergio Luis-Lima
NNN Negrin-Mena
N Negrin-Mena
EPEsteban Porrini
Esteban Porrini
Funding Acknowledgements: Type of funding sources: Public hospital(s). Main funding source(s): Complejo Hospitalario Universitario de Canarias, Tenerife -Spain. Background/Introduction: HF syndrome is a highly prevalent disease which courses with frequent readmissions, mainly by Acute Heart Failure (AHF). Worsening renal function is associated with increased mortality in patients with HF. Therefore, an accurate and precise evaluation of renal function in patients with HF is crucial. The error of estimated GFR (eGFR) is wide and common, showing ±30% of variability compared to measured GFR (mGFR). However, there is no evidence on the error of the available formulas in reflecting real renal function and particularly the consequences of this error in patients with AHF. Methods: This is a prospective pilot study comparing measured versus estimated renal function and its relationship with long-term cardiovascular (CV) outcomes in patients with AHF. A group of patients with AHF who required admission in the CICU were included. Plasma clearance of iohexol, a gold-standard method to mGFR was assessed at the same time as eGFR by five different creatinine- and cystatin c–based equations. The association between estimated or measured GFR and major CV outcomes was evaluated with univariate and multivariate logistic analysis and cox-survival analysis. The main outcome was the first onset of fatal and nonfatal major cardiovascular events during follow-up. Results: A total of 90 patients were included. Average age was 66 (± 12 years) and 52 (57,8%) were male. A total of 53 patients (59%) had a cardiovascular event during follow-up, being fatal in 22 cases (41,5%). Other variables are shown in Table 1. None of eGFR was significantly associated with the primary outcome in the unadjusted analyses. In the adjusted regression models, mGFR was significantly associated (p 0,037) with major cardiovascular events when it was correlated with NTproBNP, BMI, LVEF and previous coronary artery disease. mGFR on admission predicts future CV events compared with eGFR based on creatinine or cystatin equations. eGFR overestimates renal function showing around ±20% variability of mGFR in our AHF population (Figure 1). Conclusions: Frequently used eGFR formulas in our daily practice in AHF patients do not predict well long-term cardiovascular outcomes. Measured GFR in AHF admission predicts CV events, while eGFR reflects an important variability of the real renal function. Specific subpopulations of AHF may require better evaluation of renal function because it may have prognosis consequences.